← Aquestive Therapeutics, Inc. (AQST) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Aquestive Therapeutics, Inc. (AQST)
Pharmaceutical Preparations · market cap $607M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Aquestive Therapeutics (AQST) is a small-cap specialty pharma company (142 employees, ~$507M market cap) focused on buccal soluble film drug delivery, with its lead asset being a weight/age-dosed Diazepam Buccal Soluble Film in Phase 3 for acute repetitive seizures in epilepsy patients. The company generates modest product revenue (~$45-58M annually) but has burned heavily — net losses of $44-84M in recent years — and carries a ~22-month cash runway on $110.7M in cash.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Diazepam Buccal Film 12.5 mg | Phase 2 | Epilepsy |
| Diazepam Buccal Film | Phase 2 | Epilepsy |
| Diastat® Rectal Gel (Valeant Pharmaceuticals USA) | Phase 2 | Epilepsy |
| Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category | Phase 3 | Epilepsy |
| DESF | Phase 2 | Allergic Reaction |
Price & technical context
3-month
+5.7%
6-month
+8.5%
12-month
-23.8%
52-wk range
$2.95–$7.49
vs 50-day MA
-1.7%
vs 200-day MA
+3.2%
Realized vol
79.0%
Max drawdown
-60.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AQST (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.